Evidence map›Paper›PMID 39940911›Full record

ArticleInternational journal of molecular sciences2025

The Presence of the Endocannabinoid System in an In Vitro Model of Gorham-Stout Disease and Its Possible Role in the Pathogenesis.

Cinzia Aurilia, Gaia Palmini, Simone Donati, Irene Falsetti, Gianna Galli, Lorenzo Margheriti, Teresa Iantomasi, Arcangelo Moro, Maria Luisa Brandi

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Cinzia AuriliaDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Pieraccini 6, 50139 Florence, Italy.
Gaia PalminiFondazione Italiana Ricerca sulle Malattie dell'Osso (FIRMO Onlus), 50141 Florence, Italy.ORCID 0000-0002-8376-7404
Simone DonatiDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Pieraccini 6, 50139 Florence, Italy.
Irene FalsettiDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Pieraccini 6, 50139 Florence, Italy.
Gianna GalliDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Pieraccini 6, 50139 Florence, Italy.
Lorenzo MargheritiStabilimento Chimico Farmaceutico Militare (SCFM)-Agenzia Industrie Difesa (AID), 50141 Florence, Italy.
Teresa IantomasiDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Pieraccini 6, 50139 Florence, Italy.ORCID 0000-0001-7461-330X
Arcangelo MoroStabilimento Chimico Farmaceutico Militare (SCFM)-Agenzia Industrie Difesa (AID), 50141 Florence, Italy.
Maria Luisa BrandiFondazione Italiana Ricerca sulle Malattie dell'Osso (FIRMO Onlus), 50141 Florence, Italy.ORCID 0000-0002-8741-0592

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gorham-Stout syndrome (GSD), also known as disappearing bone disease, is an extremely rare bone disorder, characterized by a huge bone loss, which is followed by a lack of new matrix deposition and an excessive proliferation of both blood vessels and lymphatics. Unfortunately, the biological causes of GSD are still unknown. Recent studies that have tried to understand the etiopathogenesis of GSD have been principally focused on the vascular and osteoclastogenic aspects, not considering the possibility of a lack of osteoblast function. Nowadays, a diagnosis is still difficult, and is often made by exclusion of the presence of other pathologies, as well as on radiological evidence, and finally confirmed by histological examination. Treatment also remains a critical issue for clinicians today, who mostly try to control the progression of the disease. Over the last two decades, clear evidence has emerged that the endocannabinoid system plays an important role in bone metabolism, leading scientists to hypothesize that it could be involved in physiological and pathological bone processes. In this work, we analyzed the presence of the ES in a primary cell line of human mesenchymal stem cells derived from a GSD patient for the first time, to understand if and how this complex network may play a role in the pathogenesis of the syndrome. Our preliminary results demonstrated that the ES is also present in the pathological tissue. Moreover, the qRT-PCR analysis showed an altered expression of the different ES components (i.e., CNR1, CNR2, TRPV1, and GPR55). We observed an upregulation of CNR1 and TRPV1 expression, while the opposite trend was noticed for CNR2 and GPR55 expression. Thus, these results could lead us to speculate that possible deregulation of the ES may play an important role in the lack of bone regeneration in GSD patients. However, further studies will be necessary to confirm the role of the ES in the progression of GSD and understand whether the natural components of Cannabis Sativa could play a therapeutic role in the treatment of the disease.

Indexed as

EndocannabinoidsOsteolysis, EssentialCell LineHumansMesenchymal Stem CellsReceptor, Cannabinoid, CB2Receptors, CannabinoidReceptors, G-Protein-CoupledTRPV Cation ChannelsEndocannabinoidsReceptor, Cannabinoid, CB2Receptors, CannabinoidReceptors, G-Protein-CoupledTRPV Cation ChannelsESGSDhBMMSCsosteogenic differentiation

Identifiers

PMID39940911
PMCPMC11818735

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.